Team San Sanfilippo Foundation representatives told Proactive Investors the nonprofit medical research foundation has contributed grant money towards New York-based biotech Inc's () upcoming clinical study to treat Sanfillipo Syndrome.
Team San Filippo Foundation Treasurer Danielle O'Connor, along with President Kathleen Buckley and Vice President Patricia Taormino say the nonprofit will fund Seelos which will begin initial patient dosing with its SLS-005 therapy in the third quarter of 2019.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Seelos Therapeutics named herein, including the promotion by the Company of Seelos Therapeutics in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE
